Figure 6.
Figure 6. Survival for specified subsets. (A) Gemtuzumab vs idarubicin among high-risk APL patients. (B) Overall survival by cytogenetics.

Survival for specified subsets. (A) Gemtuzumab vs idarubicin among high-risk APL patients. (B) Overall survival by cytogenetics.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal